Hyperuricemia:
Indications for: ALOPRIM
Chemotherapy-induced hyperuricemia and hyperuricosuria when oral therapy not feasible.
Adult Dosage:
Give by IV infusion in single or divided doses. Start 1–2 days before chemotherapy. Adjust based on serum uric acid levels. Initially 200–400mg/m2 per day; max 600mg/day. Renal impairment: CrCl 10–20mL/min: 200mg/day; 3–10mL/min: 100mg/dose. <3mL/min: 100mg/day and extend dosing interval (see literature).
Children Dosage:
Give by IV infusion in single or divided doses. Start 1–2 days before chemotherapy. Adjust based on serum uric acid levels. Initially 200mg/m2 per day. Renal impairment: CrCl 10–20mL/min: 200mg/day; CrCl 3–10mL/min: 100mg/day; CrCl <3mL/min: 100mg/day and extend dosing interval; see literature.
ALOPRIM Contraindications:
Asymptomatic hyperuricemia.
ALOPRIM Warnings/Precautions:
Maintain adequate hydration (urine output at least 2L/day in adults) and urine alkalinization. Discontinue if rash occurs. Monitor blood counts, renal, and hepatic function for first few months of therapy. Elderly. Pregnancy (Cat.C). Nursing mothers.
ALOPRIM Classification:
Xanthine oxidase inhibitor.
ALOPRIM Interactions:
Potentiates oral anticoagulants, hypoglycemics, cyclosporine, theophylline. Antagonized by uricosurics. Monitor renal function with thiazides. Reduce concomitant azathioprine, mercaptopurine doses.
Adverse Reactions:
Rash, GI disorders, acute gout, ecchymosis, fever, headache, hepatic necrosis, drowsiness, neuritis, arthralgia, blood dyscrasias, toxic skin reactions, renal failure.
How Supplied:
Vial—1
Miscellaneous urogenital disorders:
Indications for: ALOPRIM
Chemotherapy-induced hyperuricemia and hyperuricosuria when oral therapy not feasible.
Adult Dosage:
Give by IV infusion in single or divided doses. Start 1–2 days before chemotherapy. Adjust based on serum uric acid levels. Initially 200–400mg/m2 per day; max 600mg/day. Renal impairment: CrCl 10–20mL/min: 200mg/day; 3–10mL/min: 100mg/dose. <3mL/min: 100mg/day and extend dosing interval (see literature).
Children Dosage:
Give by IV infusion in single or divided doses. Start 1–2 days before chemotherapy. Adjust based on serum uric acid levels. Initially 200mg/m2 per day. Renal impairment: CrCl 10–20mL/min: 200mg/day; CrCl 3–10mL/min: 100mg/day; CrCl <3mL/min: 100mg/day and extend dosing interval; see literature.
ALOPRIM Contraindications:
Asymptomatic hyperuricemia.
ALOPRIM Warnings/Precautions:
Maintain adequate hydration (urine output at least 2L/day in adults) and urine alkalinization. Discontinue if rash occurs. Monitor blood counts, renal, and hepatic function for first few months of therapy. Elderly. Pregnancy (Cat.C). Nursing mothers.
ALOPRIM Classification:
Xanthine oxidase inhibitor.
ALOPRIM Interactions:
Potentiates oral anticoagulants, hypoglycemics, cyclosporine, theophylline. Antagonized by uricosurics. Monitor renal function with thiazides. Reduce concomitant azathioprine, mercaptopurine doses.
Adverse Reactions:
Rash, GI disorders, acute gout, ecchymosis, fever, headache, hepatic necrosis, drowsiness, neuritis, arthralgia, blood dyscrasias, toxic skin reactions, renal failure.
How Supplied:
Vial—1
